Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI

This trial compares two cholesterol-lowering strategies after a heart attack: a low-dose combination of rosuvastatin and ezetimibe versus a high-dose rosuvastatin alone. After a heart attack treated with a stent procedure (PCI), patients need effective cholesterol control to prevent future events. This study tests whether combining two drugs at lower doses is just as effective — and perhaps better tolerated — than using one drug at a higher dose. Participants are adults 19 and older who were treated with PCI for a heart attack (STEMI or NSTEMI). Women of childbearing age must agree to pregnancy testing. You may be eligible if: - You are 19 years or older - You were diagnosed with a heart attack (ST-elevation or non-ST-elevation) and treated with percutaneous coronary intervention (PCI/stent) - You can provide informed consent You may NOT be eligible if: - You have a life expectancy of 1 year or less due to cancer - You have chronic liver disease - You are allergic to rosuvastatin or ezetimibe, or cannot take them - You are pregnant or breastfeeding - You cannot use any form of contraception (for women of childbearing age) - You are on dialysis or have had a kidney transplant - You participated in another clinical trial within the past 3 months Talk to your doctor to see if this trial is right for you.